시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 CC 케모카인 수용체 5형 시장 보고서(2025년)
CC Chemokine Receptor Type 5 Global Market Report 2025
상품코드 : 1825651
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,546,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,462,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,378,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

CC 케모카인 수용체 5형 시장 규모는 향후 몇 년 동안 급성장할 것으로 예측됩니다. 2029년에는 22억 6,000만 달러로 성장하여 CAGR 10.0%를 보일 것으로 예측됩니다. 예측 기간의 성장은 HIV 또는 AIDS의 확산, 의료 인프라, 경제적 인센티브, 의료 수요 증가, 경제 성장에 기인한다고 볼 수 있습니다. 예측 기간의 주요 동향으로는 암 치료 관련 연구개발 확대, 병용요법 개발, 의약품 제조 개발, 전략적 제휴 및 파트너십, 임상시험 확대 등을 들 수 있습니다.

향후 5년간의 성장률 10.0%는 지난번 전망치보다 0.2% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 스위스나 영국에서 조달하는 CCR5(CCR5) 수용체 길항제 및 유전자 편집 도구의 비용을 상승시킴으로써 미국의 인간면역결핍바이러스(HIV) 연구를 저해하고, 혁신적인 치료법을 지연시키며, 감염성 질환의 연구개발비용을 상승시킬 것으로 예측됩니다. 또한, 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

만성 질환의 유병률 증가는 향후 몇 년 동안 CCR5(CCR5) 시장의 성장을 견인할 것으로 예측됩니다. 만성질환은 심장병, 당뇨병, 관절염과 같은 장기적인 질환으로 서서히 진행되어 일반적으로 지속적인 관리가 필요한 질환입니다. 만성질환 증가는 인구의 고령화, 식습관 장애, 운동 부족, 비만 등 생활습관 관련 위험요인 증가에 기인합니다. CCR5는 인간면역결핍바이러스(HIV)와 같은 만성질환에서 중요한 역할을 하며, 면역세포에 바이러스의 침입을 촉진하고 질병 진행에 기여하는 핵심 수용체로 작용합니다. 예를 들어, 2023년 10월 스위스에 본부를 둔 HIV 예방에 초점을 맞춘 세계 이니셔티브인 유엔 합동 에이즈 프로그램(Joint United Nations Programme on HIV/AIDS)은 2021년에는 약 3,870만 명이 HIV에 감염될 것이며, 그 숫자는 2022년에는 3,900만 명으로 증가할 것이며, 그 중에는 같은 해 신규 감염자 130만 명도 포함될 것이라고 보고했습니다. 그 결과, 만성질환 유병률 증가는 CCR5 시장의 성장을 가속하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

LSH
영문 목차

영문목차

CC chemokine receptor type 5 (CCR5) is a protein found on the surface of white blood cells that plays a crucial role in the immune system by serving as a receptor for specific chemokines. These signaling molecules guide the movement of immune cells to areas of inflammation or infection. CCR5 is notably involved in the pathogenesis of diseases such as HIV, where it acts as a co-receptor, enabling the virus to enter and infect host cells, thus making it a target for therapeutic interventions.

The main types of CCR5-related compounds include BMS-813160, AG-1105, CCL-14, DS-001, and others. BMS-813160 is a small-molecule inhibitor developed by Bristol-Myers Squibb, designed to target specific receptors or pathways and is often investigated for its potential therapeutic effects in diseases such as cancer. Distribution channels for these compounds include hospitals, clinics, online pharmacies, and retail pharmacies. They are applied in various fields, including infectious diseases, gastrointestinal conditions, immunology, and oncology, and are used by different end-users such as research institutes, pharmaceutical companies, and healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The CC chemokine receptor type 5 market research report is one of a series of new reports from The Business Research Company that provides CC chemokine receptor type 5 market statistics, including CC chemokine receptor type 5 industry global market size, regional shares, competitors with an CC chemokine receptor type 5 market share, detailed CC chemokine receptor type 5 market segments, market trends, and opportunities, and any further data you may need to thrive in the CC chemokine receptor type 5 industry. This CC chemokine receptor type 5 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cc chemokine receptor type 5 market size has grown rapidly in recent years. It will grow from $1.4 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to government funding, R&D collaborations, public health campaigns, public-private partnerships, and the discovery of CCR5.

The cc chemokine receptor type 5 market size is expected to see rapid growth in the next few years. It will grow to $2.26 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to the prevalence of HIV or AIDS, healthcare infrastructure, economic incentives, increasing demand for healthcare, and economic growth. Major trends in the forecast period include expanding research on cancer treatment, development of combination therapies, development of pharmaceutical manufacturing, strategic collaborations and partnerships, and clinical trials expansion.

The forecast of 10.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. Human Immunodeficiency Virus(HIV) research by increasing the cost of CC chemokine receptor 5(CCR5) antagonist drugs and gene editing tools sourced from Switzerland and the UK, thereby delaying innovative therapies and elevating infectious disease R&D costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of chronic diseases is expected to drive the expansion of the CC chemokine receptor type 5 (CCR5) market in the coming years. Chronic diseases are long-term medical conditions, such as heart disease, diabetes, and arthritis, which progress gradually and typically require ongoing management. The rise in chronic diseases can be attributed to aging populations and increasing rates of lifestyle-related risk factors, including poor diet, lack of physical activity, and obesity. CCR5 plays a key role in chronic diseases like human immunodeficiency virus (HIV), acting as a coreceptor that facilitates the virus's entry into immune cells and contributes to the disease's progression. For example, in October 2023, the Joint United Nations Programme on HIV/AIDS, a Switzerland-based global initiative focused on HIV prevention, reported that in 2021, approximately 38.7 million people were living with HIV, with the number rising to 39.0 million in 2022, including 1.3 million new infections that year. Consequently, the increasing prevalence of chronic diseases is fueling the growth of the CCR5 market.

Companies in the CCR5 market are focusing on developing new drugs, such as CCR5 antagonists, to maintain a competitive edge. CCR5 antagonists are medications that block the CCR5 receptor on immune cells, preventing certain pathogens such as HIV from binding and entering these cells, thereby inhibiting infection and influencing immune responses. For instance, in February 2024, CytoDyn Inc., a US-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on leronlimab, a CCR5 antagonist also known as PRO 140. This approval allows CytoDyn to proceed with its planned clinical trial to evaluate leronlimab's effects on chronic inflammation. Leronlimab shows potential for treating various health conditions, including HIV and cancer, due to its ability to target multiple diseases.

In October 2022, Amgen Inc., a US-based biopharmaceutical company, acquired ChemoCentryx for approximately $3.7 billion. This acquisition is aimed at enhancing Amgen's portfolio in inflammation and nephrology by incorporating ChemoCentryx's innovative therapeutics, such as TAVNEOS (avacopan), into its product lineup. ChemoCentryx is a US-based company specializing in CCR5-related medicines.

Major companies operating in the cc chemokine receptor type 5 market are Pfizer Inc., Sorrento Therapeutics, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Avexa Limited, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Gilead Sciences Inc., Vertex Pharmaceuticals, Ono Pharmaceutical Co Ltd, Abcam Limited, BioLegend Inc., R&D Systems Inc, American Gene Technologies International Inc, NSJ Bioreagents, Cytodyn Inc., Affinity Biosciences

North America was the largest region in the CC chemokine receptor type 5 market in 2024. The regions covered in the cc chemokine receptor type 5 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cc chemokine receptor type 5 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CC chemokine receptor type 5 market consists of sales of receptor antagonists, monoclonal antibodies, small molecule inhibitors, and gene editing therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CC Chemokine Receptor Type 5 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cc chemokine receptor type 5 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cc chemokine receptor type 5 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cc chemokine receptor type 5 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. CC Chemokine Receptor Type 5 Market Characteristics

3. CC Chemokine Receptor Type 5 Market Trends And Strategies

4. CC Chemokine Receptor Type 5 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global CC Chemokine Receptor Type 5 Growth Analysis And Strategic Analysis Framework

6. CC Chemokine Receptor Type 5 Market Segmentation

7. CC Chemokine Receptor Type 5 Market Regional And Country Analysis

8. Asia-Pacific CC Chemokine Receptor Type 5 Market

9. China CC Chemokine Receptor Type 5 Market

10. India CC Chemokine Receptor Type 5 Market

11. Japan CC Chemokine Receptor Type 5 Market

12. Australia CC Chemokine Receptor Type 5 Market

13. Indonesia CC Chemokine Receptor Type 5 Market

14. South Korea CC Chemokine Receptor Type 5 Market

15. Western Europe CC Chemokine Receptor Type 5 Market

16. UK CC Chemokine Receptor Type 5 Market

17. Germany CC Chemokine Receptor Type 5 Market

18. France CC Chemokine Receptor Type 5 Market

19. Italy CC Chemokine Receptor Type 5 Market

20. Spain CC Chemokine Receptor Type 5 Market

21. Eastern Europe CC Chemokine Receptor Type 5 Market

22. Russia CC Chemokine Receptor Type 5 Market

23. North America CC Chemokine Receptor Type 5 Market

24. USA CC Chemokine Receptor Type 5 Market

25. Canada CC Chemokine Receptor Type 5 Market

26. South America CC Chemokine Receptor Type 5 Market

27. Brazil CC Chemokine Receptor Type 5 Market

28. Middle East CC Chemokine Receptor Type 5 Market

29. Africa CC Chemokine Receptor Type 5 Market

30. CC Chemokine Receptor Type 5 Market Competitive Landscape And Company Profiles

31. CC Chemokine Receptor Type 5 Market Other Major And Innovative Companies

32. Global CC Chemokine Receptor Type 5 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The CC Chemokine Receptor Type 5 Market

34. Recent Developments In The CC Chemokine Receptor Type 5 Market

35. CC Chemokine Receptor Type 5 Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기